Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03915951 · ADVERSE EVENTS

Adverse events

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer · Source last updated 2026-03-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
From the time the participant provided informed consent, through and including a minimum of 30 calendar days, after the last administration of the study intervention, and the safety follow-up visit (30 days [±7 days] after the EOT visit) (up to 36 months)
Other-event reporting threshold
5%

Same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both serious and non-serious event during the study. Safety analysis set included all participants who received at least 1 dose of study intervention.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Treatment-Naive

Treatment-naïve participants with BRAF V600E-mutant metastatic NSCLC were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.

25 / 5959 / 595 / 59
Previously Treated

Patients who had received 1) first-line treatment with standard platinum-based chemotherapy, or 2) first-line treatment with an anti-PD-1/PD-L1 inhibitor given alone, or in combination with platinum-based chemotherapy, or in combination with immunotherapy (eg, ipilimumab) with or without platinum-based chemotherapy were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID was to be administered in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.

17 / 3938 / 397 / 39
Total

Sum of all participants in the Study C4221008 (ARRAY-818-202)

42 / 9897 / 9812 / 98

Group identifiers: EG000: Treatment-Naive · EG001: Previously Treated · EG002: Total

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      3
      num At Risk
      98
    term
    Anaemia
  2. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Disseminated intravascular coagulation
  3. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      2
      num At Risk
      98
    term
    Myocardial infarction
  4. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Atrial fibrillation
  5. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Pericardial effusion
  6. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Supraventricular tachyarrhythmia
  7. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Tachycardia
  8. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Retinal detachment
  9. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      98
    term
    Colitis
  10. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Constipation
  11. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Diarrhoea
  12. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Duodenal ulcer

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      20
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      10
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      30
      num At Risk
      98
    term
    Anaemia
  2. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      14
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Vision blurred
  3. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      37
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      19
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      56
      num At Risk
      98
    term
    Nausea
  4. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      29
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      20
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      49
      num At Risk
      98
    term
    Diarrhoea
  5. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      23
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      13
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      36
      num At Risk
      98
    term
    Vomiting
  6. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      18
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      26
      num At Risk
      98
    term
    Constipation
  7. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      14
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Abdominal pain
  8. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      8
      num At Risk
      98
    term
    Abdominal pain upper
  9. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      29
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      16
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      45
      num At Risk
      98
    term
    Fatigue
  10. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      16
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      22
      num At Risk
      98
    term
    Pyrexia
  11. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Oedema peripheral
  12. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      9
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      16
      num At Risk
      98
    term
    Asthenia
Complete source fields
description
Same event may appear as both an AE and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both serious and non-serious event during the study. Safety analysis set included all participants who received at least 1 dose of study intervention.
event Groups
  1. deaths Num Affected
    5
    deaths Num At Risk
    59
    description
    Treatment-naïve participants with BRAF V600E-mutant metastatic NSCLC were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.
    id
    EG000
    other Num Affected
    59
    other Num At Risk
    59
    serious Num Affected
    25
    serious Num At Risk
    59
    title
    Treatment-Naive
  2. deaths Num Affected
    7
    deaths Num At Risk
    39
    description
    Patients who had received 1) first-line treatment with standard platinum-based chemotherapy, or 2) first-line treatment with an anti-PD-1/PD-L1 inhibitor given alone, or in combination with platinum-based chemotherapy, or in combination with immunotherapy (eg, ipilimumab) with or without platinum-based chemotherapy were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID was to be administered in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.
    id
    EG001
    other Num Affected
    38
    other Num At Risk
    39
    serious Num Affected
    17
    serious Num At Risk
    39
    title
    Previously Treated
  3. deaths Num Affected
    12
    deaths Num At Risk
    98
    description
    Sum of all participants in the Study C4221008 (ARRAY-818-202)
    id
    EG002
    other Num Affected
    97
    other Num At Risk
    98
    serious Num Affected
    42
    serious Num At Risk
    98
    title
    Total
frequency Threshold
5
other Events
  1. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      20
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      10
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      30
      num At Risk
      98
    term
    Anaemia
  2. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      14
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Vision blurred
  3. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      37
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      19
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      56
      num At Risk
      98
    term
    Nausea
  4. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      29
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      20
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      49
      num At Risk
      98
    term
    Diarrhoea
  5. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      23
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      13
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      36
      num At Risk
      98
    term
    Vomiting
  6. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      18
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      26
      num At Risk
      98
    term
    Constipation
  7. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      14
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Abdominal pain
  8. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      8
      num At Risk
      98
    term
    Abdominal pain upper
  9. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      29
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      16
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      45
      num At Risk
      98
    term
    Fatigue
  10. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      16
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      22
      num At Risk
      98
    term
    Pyrexia
  11. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      12
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      20
      num At Risk
      98
    term
    Oedema peripheral
  12. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      9
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      16
      num At Risk
      98
    term
    Asthenia
serious Events
  1. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      3
      num At Risk
      98
    term
    Anaemia
  2. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Disseminated intravascular coagulation
  3. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      2
      num At Risk
      98
    term
    Myocardial infarction
  4. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Atrial fibrillation
  5. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Pericardial effusion
  6. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Supraventricular tachyarrhythmia
  7. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Tachycardia
  8. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Retinal detachment
  9. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      98
    term
    Colitis
  10. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Constipation
  11. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Diarrhoea
  12. assessment Type
    NON_SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA version 25.0
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      59
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      39
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      98
    term
    Duodenal ulcer
time Frame
From the time the participant provided informed consent, through and including a minimum of 30 calendar days, after the last administration of the study intervention, and the safety follow-up visit (30 days [±7 days] after the EOT visit) (up to 36 months)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice